Every Form 4 that Nurix Therapeutics, Inc. (NRIX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NRIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRIX filings page.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring exercised 5,786 stock options on October 2, 2026, at an exercise price of $8.72 per share, acquiring 5,786 common shares. She sold 5,786 common shares that day at a weighted average price of $23.1851 per share; the sale was made under a previously adopted Rule 10b5-1 trading plan. Reported option holdings after the exercise were 111,251.
Nurix Therapeutics, Inc. (NRIX) reported that Chief Legal Officer Christine Ring exercised employee stock options for 5,787 shares of common stock on September 2, 2026 at an exercise price of $8.72 per share, converting them into common stock. These options were part of a grant vesting monthly from March 13, 2024 until February 13, 2027, and following this exercise 117,037 options remain outstanding from the grant. On the same date, she sold 5,387 shares of common stock at a weighted average price of $25.6947 per share and 400 shares at a weighted average price of $26.6375 per share, in each case in transactions carried out under a previously adopted Rule 10b5-1 trading plan.
Nurix Therapeutics, Inc. (NRIX) reported that Chief Scientific Officer Gwenn Hansen exercised employee stock options for 1,452 shares of common stock at an exercise price of $1.86 per share and on the same date sold 1,452 shares at $25.47 per share. Following the option exercise, Hansen held 60,858 stock options directly, expiring on August 28, 2029. The transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
Nurix Therapeutics, Inc. reported that Chief Scientific Officer Gwenn Hansen exercised employee stock options for 4,356 shares at an exercise price of $1.8600 per share and sold 4,356 common shares at $25.0000 per share on August 5, 2026 under a Rule 10b5-1 trading plan. After the exercise, 62,310 options from this grant remained outstanding, with an option expiration date of 2029-08-28.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported selling a total of 4,111 shares of common stock on 2026-08-04 in two transactions at weighted average prices of $23.8684 and $24.6415. The sales were effected pursuant to a previously adopted Rule 10b5-1 trading plan.
Nurix Therapeutics, Inc. reported that Chief Financial Officer Hans van Houte sold a total of 4,761 shares of common stock on August 4, 2026, in two open-market or private transactions at weighted average prices of $23.8911 and $24.6474 per share pursuant to a previously adopted Rule 10b5-1 trading plan, with sale prices ranging between $23.42 and $24.83.
Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised employee stock options for 5,787 shares of common stock at an exercise price of $8.72 per share and, on the same date, sold 16,589 common shares at a weighted average price of $23.0489 (within a $22.67–$23.30 range). Following the option exercise, 122,824 stock options tied to common stock remain outstanding, expiring in 2034. These transactions were effected under a previously adopted Rule 10b5-1 trading plan.
Nurix Therapeutics, Inc. reported that CFO Hans van Houte exercised three tranches of restricted stock units, converting 10,180 RSUs into the same number of common shares at a $0 exercise price. He then sold 2,845 shares at a weighted average price of $23.3828, within a $23.00–$23.90 range, solely to cover RSU-related tax withholding under a mandatory “sell to cover” arrangement, rather than as discretionary trades.
Nurix Therapeutics, Inc. reported insider activity by Chief Legal Officer Christine Ring on July 30, 2026. Three RSU tranches of 3,750, 2,858, and 3,572 units (total 10,180) vested and converted into the same number of common shares at a $0.00 exercise price. On the same date, 3,847 common shares were sold at a weighted average price of $23.3828 per share to cover tax withholding obligations through a mandatory “sell to cover” mechanism under the issuer’s equity plans, and the filing notes these were not discretionary trades.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported the vesting and conversion of 10,180 Restricted Stock Units into an equal number of shares of common stock on July 30, 2026, at an exercise price of $0.00 per share.
On the same date, Hansen sold 3,847 shares of common stock at a weighted average price of $23.3828 per share, within a range of $23.00 to $23.90. According to the disclosure, these shares were sold solely to cover tax withholding obligations under the company’s equity incentive plans through a mandated "sell to cover" transaction and were not discretionary trades.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an option exercise-and-sale transaction in company stock. She exercised employee stock options to acquire a total of 11,008 shares of common stock at exercise prices of $8.72 and $1.86 per share, then sold 11,008 shares in an open-market sale at a weighted average price of $23.5616 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she directly holds 13,579 shares of common stock and retains an employee stock option covering 128,611 shares at an exercise price of $8.72 per share, expiring on February 12, 2034.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen executed an open-market sale of 5,394 shares of Common Stock at $20.00 per share. The transaction was carried out under a previously adopted Rule 10b5-1 trading plan, indicating it was pre-scheduled rather than timed discretionarily. Following this sale, Hansen holds 115,005 shares directly, so the filing reflects a relatively small, planned reduction in her overall position.
Nurix Therapeutics Chief Legal Officer Christine Ring exercised stock options and sold the resulting shares in a pre-planned trade. On the reported date, she exercised options for 28,935 shares of common stock at strike prices of $8.72 and $7.26 per share and sold 28,935 shares in open-market transactions at a weighted average price of $20.0624 per share, pursuant to a Rule 10b5-1 trading plan. Following these transactions, the filing reports that she holds 13,579 shares of common stock directly and continues to hold employee stock options, including 134,398 options with a $8.72 exercise price expiring in 2034.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an open-market sale and an option exercise involving the company’s common stock. She sold 8,148 shares of common stock at a weighted average price of $16.5995 per share under a pre-arranged Rule 10b5-1 trading plan, with sale prices ranging from $16.35 to $17.10. In a related move, she exercised employee stock options covering 3,422 shares at an exercise price of $1.86 per share, converting them into common stock. Following these transactions, she directly holds 13,579 shares of common stock and 5,221 employee stock options.
Nurix Therapeutics director Paul M. Silva received a new stock option grant covering 31,250 shares of Common Stock. The option has an exercise price of $15.86 per share and expires on May 14, 2036.
The option vests in full on the earlier of the company’s next annual stockholder meeting or May 15, 2027, in each case only if Silva continues providing service to the company through the vesting date. Following this grant, he holds stock options for 31,250 shares directly.
Nurix Therapeutics director Edward C. Saltzman received a stock option grant for 31,250 shares of common stock. The option has an exercise price of $15.86 per share and expires on May 14, 2036. All 31,250 underlying shares are reported as held directly after this award.
The option vests in full on the earlier of the company’s next annual stockholder meeting or May 15, 2027, assuming Mr. Saltzman continues to provide service to Nurix through the vesting date. This is a compensation-related grant, not an open-market share purchase or sale.
Nurix Therapeutics, Inc. director Judith A. Reinsdorf received a grant of stock options covering 31,250 shares of common stock. The options have an exercise price of $15.86 per share and expire on May 14, 2036. The entire award vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, subject to her continued service, giving her 31,250 options beneficially owned after this grant.
Nurix Therapeutics director David L. Lacey received a grant of stock options covering 31,250 shares of common stock. The options have an exercise price of $15.86 per share and are held directly. Following this award, he holds options on 31,250 shares.
The option grant vests in full on the earlier of the company’s next annual stockholder meeting or May 15, 2027, in each case only if he continues providing service to Nurix on that vesting date. The options expire on May 14, 2036 if not exercised.
Nurix Therapeutics director Anil Kapur received a stock option grant covering 31,250 shares of common stock. The option has an exercise price of $15.86 per share and expires on May 14, 2036. This is a compensation-related award, not an open-market purchase.
The option vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, as long as Kapur continues providing service to Nurix through the vesting date. After this grant, his directly held option position from this award totals 31,250 underlying shares.
Nurix Therapeutics, Inc. reported a Form 4 showing director Roger D. Dansey received a grant of stock options for 31,250 shares of common stock at an exercise price of $15.86 per share. The option vests 100% on the earlier of the next annual stockholder meeting or May 15, 2027, subject to continued service, and expires on May 14, 2036. This is a compensation-related award, not an open-market trade.
Nurix Therapeutics director Roy D. Baynes received a grant of 31,250 stock options to buy Nurix common stock. The options have an exercise price of $15.86 per share and expire on May 14, 2036, providing long-term equity-based compensation.
The award vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, so long as Baynes continues to provide service through the vesting date. After this grant, he holds 31,250 derivative securities linked to Nurix common stock directly.
Nurix Therapeutics, Inc. director Julia P. Gregory received a grant of stock options covering 31,250 shares of common stock. These options have an exercise price of $15.8600 per share and expire on May 14, 2036.
The award vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, as long as she continues providing service to the company through that vesting date. This is a compensation-related grant, not an open-market purchase or sale.
Nurix Therapeutics, Inc.’s Chief Financial Officer Hans van Houte reported open-market sales of company stock. On May 5, 2026, he sold a total of 14,055 shares of common stock in two transactions pursuant to a previously adopted Rule 10b5-1 trading plan.
The reported sales covered 13,473 shares at $16.5756 per share and 582 shares at $17.1751 per share, each representing a weighted average sale price across multiple trades within stated price ranges.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an open-market sale of 8,148 shares of common stock at a weighted average price of $16.9624 per share. The transaction was executed pursuant to a previously adopted Rule 10b5-1 trading plan. Following this sale, she holds 18,305 shares directly.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an open-market sale of 5,394 shares of common stock on May 1, 2026 at a weighted average price of $16.7606 per share. The sale was executed under a previously adopted Rule 10b5-1 trading plan, with individual sale prices ranging from $16.26 to $16.97. Following this transaction, she directly holds 26,453 shares of Nurix common stock.
Nurix Therapeutics Chief Financial Officer Hans van Houte reported routine equity compensation activity tied to restricted stock units (RSUs). On April 30, 2026, RSUs covering 8,608 shares of common stock vested and were converted into common shares.
To satisfy associated tax withholding obligations, 2,388 common shares were sold in an open-market transaction at a weighted average price of $16.6453 per share. The company’s equity plan required this "sell to cover" transaction, and the filing states it did not represent a discretionary trade by the executive.
Following these transactions, Hans van Houte directly holds 51,647 shares of Nurix common stock. The RSU awards vest in quarterly installments over three years, with separate grants beginning to vest on July 30, 2023, July 30, 2024, and July 30, 2025, contingent on continued service. Each RSU represents a right to receive one share of common stock upon vesting.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring had restricted stock units vest and related share movements on April 30, 2026. She sold 3,214 shares of common stock at a weighted average of $16.6453 per share solely to cover tax withholding on the RSU vesting, under the company’s mandatory “sell to cover” policy, so the sale was not a discretionary trade. In connection with the vesting, she acquired a total of 8,608 shares of common stock through RSU conversions.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported compensation-related stock activity involving vested restricted stock units and a small mandated share sale. On April 30, 2026, she exercised RSUs into a total of 8,608 shares of common stock.
On the same date, she sold 3,214 shares of common stock at a weighted average price of $16.6453 per share solely to cover tax withholding obligations under Nurix’s equity incentive plans. These “sell to cover” transactions were not discretionary trades. After these transactions, she held 120,399 common shares directly.
Nurix Therapeutics Chief Legal Officer Christine Ring sold 8,148 shares of common stock in an open-market transaction. The weighted average sale price was $15.2367 per share, with individual trades ranging from $15.00 to $15.43. Following the sale, she directly holds 26,453 Nurix shares. The transaction was executed under a previously adopted Rule 10b5-1 trading plan, indicating it was pre-scheduled rather than a discretionary trade.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring sold 8,148 shares of common stock in an open-market transaction on March 2, 2026. The shares were sold at a weighted average price of $15.4385 per share under a previously adopted Rule 10b5-1 trading plan. Following this sale, she directly holds 34,601 Nurix shares.
Nurix Therapeutics Chief Financial Officer Hans van Houte received new equity awards in the form of stock options and restricted stock units. On February 10, 2026, he was granted an employee stock option for 93,750 shares of common stock at an exercise price of $16.45 per share, vesting in equal monthly installments over three years until February 9, 2029, while he continues serving the company.
He was also granted 42,875 restricted stock units, each representing one share of common stock. These RSUs vest in equal quarterly installments over three years, with the first portion vesting on July 30, 2026, contingent on his continued service; vested shares will be delivered after each vesting date.
Nurix Therapeutics Chief Legal Officer receives new equity awards. On February 10, 2026, Christine Ring was granted an employee stock option for 93,750 shares of common stock at an exercise price of $16.45 per share and 42,875 restricted stock units.
The stock option vests in equal monthly installments over 36 months beginning March 10, 2026, and is fully vested by February 9, 2029, contingent on continued service. The RSUs vest in 12 quarterly installments over three years starting July 30, 2026, with one share of common stock delivered for each vested unit.
Nurix Therapeutics, Inc. reported that Chief Scientific Officer Gwenn Hansen received new equity awards on February 10, 2026. She was granted an option to buy 93,750 shares of common stock at $16.45 per share, vesting monthly over three years through February 9, 2029, subject to continued service.
Hansen was also granted 42,875 restricted stock units, each representing one share of common stock. These RSUs vest in 12 equal quarterly installments over three years, beginning July 30, 2026, with shares delivered after each vesting date as long as she remains in service.
Nurix Therapeutics President and CEO Arthur T. Sands received an employee stock option grant covering 562,500 shares of common stock at an exercise price of $16.45 per share on February 10, 2026.
The option vests in 36 equal monthly installments beginning March 10, 2026, and becomes fully vested on February 9, 2029, subject to his continued service. It is scheduled to expire on February 9, 2036.
Nurix Therapeutics’ Chief Legal Officer, Christine Ring, reported a planned sale of company stock. On 02/09/2026 she sold 14,261 shares of Nurix common stock at a weighted average price of $16.6621 per share under a pre‑arranged Rule 10b5‑1 trading plan. Following this sale, she beneficially owns 42,749 shares of Nurix common stock directly.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported an option exercise and corresponding stock acquisition. On 02/03/2026, Hansen exercised an employee stock option for 31,333 shares of common stock at $0.84 per share, converting the derivative position to common stock. Following this transaction, Hansen directly beneficially owns 115,005 shares of Nurix common stock, and the reported option grant is fully vested with 0 derivative securities remaining.
Nurix Therapeutics, Inc.’s Chief Financial Officer, Hans van Houte, reported routine equity compensation activity and related tax sales. On January 30, 2026, several blocks of restricted stock units (RSUs) converted into common stock at $0 exercise price, including 2,887, 2,000, 3,750 and 2,859 RSUs.
To cover tax withholding from these RSU vestings, the CFO sold 3,588 shares at a weighted average price of $16.5826 and 73 shares at a weighted average price of $17.3717. The filing states these are mandatory “sell to cover” transactions, not discretionary trades. After the transactions, he directly owned 45,427 common shares and 25,725 RSUs.
Nurix Therapeutics Chief Legal Officer Christine Ring reported RSU vesting and related share sales. On January 30, 2026, multiple blocks of restricted stock units were converted into common stock at an exercise price of $0, increasing her directly held common shares.
On the same date, she sold 4,333 and 88 common shares at weighted average prices of $16.5826 and $17.3717, respectively. A footnote explains these sales were mandated "sell to cover" transactions to satisfy tax withholding on RSU vesting, not discretionary trades. After these transactions, she directly owned 57,010 common shares and held 25,725 RSUs.
Nurix Therapeutics Chief Scientific Officer Gwenn Hansen reported RSU vesting and related tax-share sales. On January 30, 2026, RSUs covering 3,207, 2,000, 3,750, and 2,859 shares were converted into common stock at $0 per share.
To cover tax withholding from these RSU vestings, Hansen sold 4,797 and 98 common shares in mandated “sell to cover” transactions at weighted average prices of $16.5826 and $17.3717. After these trades, Hansen directly beneficially owned 83,672 common shares and held 25,725 RSUs.
Nurix Therapeutics, Inc. insider activity: Chief Legal Officer Christine Ring reported option exercises and share sales in Nurix Therapeutics, Inc. common stock. On 01/20/2026, she exercised 3,760 employee stock options at an exercise price of $1.86 per share, acquiring 3,760 shares of common stock. That same day, she sold 3,760 shares of common stock at a weighted average price of $18.4237 per share under a previously adopted Rule 10b5-1 trading plan. After these transactions, she beneficially owned 50,897 shares of common stock directly and 8,643 stock options.
Nurix Therapeutics, Inc. insider transaction: The company’s Chief Legal Officer, identified as the reporting person, exercised an employee stock option to acquire 3,760 shares of Nurix common stock at an exercise price of $1.86 per share on 12/18/2025. The same day, the insider sold 3,560 shares of common stock at a weighted average price of $17.8661 per share and an additional 200 shares at a weighted average price of $18.555 per share.
These transactions were carried out under a previously adopted Rule 10b5-1 trading plan. After these transactions, the reporting person beneficially owned 50,897 shares of Nurix common stock directly and held 12,403 employee stock options. The option exercised on this date had fully vested by August 9, 2023.
Nurix Therapeutics, Inc. reported an insider equity transaction by its Chief Legal Officer, Christine Ring. On 11/24/2025, she exercised an employee stock option to acquire 37,600 shares of common stock at an exercise price of $1.86 per share, then sold 37,600 shares of common stock on the same date at a weighted average price of $17.0664 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she beneficially owned 50,897 shares of Nurix common stock directly and 16,163 employee stock options.
Nurix Therapeutics (NRIX) reported a director stock option grant on a Form 4. The filing shows 50,000 options to purchase common stock at an exercise price of $12.52, granted on November 6, 2025, with an expiration date of November 6, 2035.
The option vests as to 1/36 of the total shares monthly beginning December 6, 2025 until fully vested on November 6, 2028, subject to continued service. Ownership is reported as Direct.
Nurix Therapeutics (NRIX) reported an insider transaction by its Chief Financial Officer. On 11/03/2025, the CFO sold 6,284 shares of common stock in an open-market transaction pursuant to a previously adopted Rule 10b5-1 trading plan.
The sale had a weighted average price of $12.5607, with individual sales ranging from $12.32 to $13.14. Following the transaction, the officer beneficially owns 37,592 shares directly.
Nurix Therapeutics (NRIX) Form 4: Chief Financial Officer Hans van Houte reported RSU-to-share conversions and a tax-related sale on 10/30/2025. Multiple RSU tranches converted to common stock at no cost: 2,886, 2,000, 3,750, and 2,858 shares. To cover withholding taxes tied to these vestings, he executed a mandated “sell-to-cover” of 3,130 shares at a weighted average price of $12.7967.
Following these transactions, he beneficially owned 43,876 shares of common stock directly. The RSUs vest quarterly under existing schedules, and each RSU represents the right to receive one share upon vesting.
Nurix Therapeutics (NRIX) reported insider activity by its Chief Legal Officer, Christine Ring. On 10/30/2025, multiple restricted stock unit (RSU) vestings converted into common stock via code “M” totaling 10,532 shares (1,924; 2,000; 3,750; 2,858), each at $0 per the RSU terms. A subsequent sale of 3,644 shares at a weighted average price of $12.7967 was executed to cover tax withholding obligations under a required “sell-to-cover” arrangement.
Following these transactions, the reporting person held 50,897 shares directly. Each RSU represents a right to receive one share upon vesting, with tranches vesting quarterly pursuant to previously granted awards.
Nurix Therapeutics (NRIX) reported an insider transaction by its Chief Scientific Officer on Form 4. On 10/30/2025, multiple restricted stock unit (RSU) vestings were settled into common stock, including 3,207; 2,000; 3,750; and 2,858 shares at $0 per share. The insider also sold 4,087 shares at a weighted average price of $12.7967 to satisfy tax withholding via a mandated “sell to cover.” Following these transactions, the insider directly owned 76,751 shares.
Nurix Therapeutics (NRIX) filed a Form 4 reporting an equity grant to its Chief Scientific Officer. On 10/14/2025, the reporting person received 20,000 restricted stock units (RSUs), each representing a right to receive one share of Nurix common stock.
The RSUs were reported at a price of $0 for the derivative security and are held as direct ownership. The award will vest on the second anniversary of the date of grant, contingent on continuous service through that date, after which shares will be delivered. RSUs do not have an expiration date; they either vest or are canceled prior to vesting.